New injection aims to ease Post-Surgery pain without opioids

NCT ID NCT07533786

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called HSK55718 for pain after abdominal surgery. About 200 adults will receive either the new drug, morphine, or a placebo. Researchers will measure pain relief and satisfaction. The goal is to see if HSK55718 is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HSK55718 injection

What this could lead to

If successful, this could provide a new option for managing pain after abdominal surgery with potentially fewer side effects than morphine.

What could go wrong

This is an early Phase 2 trial with only 200 people, so results may not apply to everyone. The drug may not work better than existing treatments or could have unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN AFTER SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Third Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••